HK1199026A1 - Tenofovir alafenamide hemifumarate (tenofoviralafenamide) - Google Patents

Tenofovir alafenamide hemifumarate (tenofoviralafenamide)

Info

Publication number: HK1199026A1
Authority: HK; Hong Kong
Prior art keywords: tenofoviralafenamide; tenofovir alafenamide; alafenamide hemifumarate; hemifumarate; tenofovir
Prior art date: 2011-08-16

Application number

HK14112467.3A

Other languages

English (en)

Chinese (zh)

Inventor

Dazhan Liu

Bing Shi

Fang Wang

Richard Hung Chiu Yu

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-16

Filing date

2014-12-11

Publication date

2015-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-11 Application filed filed Critical

2015-06-19 Publication of HK1199026A1 publication Critical patent/HK1199026A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

HK14112467.3A 2011-08-16 2014-12-11 Tenofovir alafenamide hemifumarate (tenofoviralafenamide) HK1199026A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161524224P	2011-08-16	2011-08-16
PCT/US2012/050920 WO2013025788A1 (en)	2011-08-16	2012-08-15	Tenofovir alafenamide hemifumarate

Publications (1)

Publication Number	Publication Date
HK1199026A1 true HK1199026A1 (en)	2015-06-19

Family

ID=46785793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK14112467.3A HK1199026A1 (en)	2011-08-16	2014-12-11	Tenofovir alafenamide hemifumarate (tenofoviralafenamide)

Country Status (42)

Country	Link
US (2)	US8754065B2 (es)
EP (3)	EP3070088A1 (es)
JP (5)	JP5651275B2 (es)
KR (1)	KR101612642B1 (es)
CN (2)	CN110343135A (es)
AP (1)	AP3639A (es)
AR (1)	AR087546A1 (es)
AU (1)	AU2012296622C1 (es)
BR (1)	BR112014003420B1 (es)
CA (1)	CA2845553C (es)
CL (1)	CL2014000370A1 (es)
CO (1)	CO6880063A2 (es)
CR (1)	CR20140072A (es)
CY (1)	CY1118385T1 (es)
DK (1)	DK2744810T4 (es)
EA (1)	EA027768B1 (es)
EC (1)	ECSP14013206A (es)
ES (1)	ES2608871T5 (es)
FI (1)	FI2744810T4 (es)
HK (1)	HK1199026A1 (es)
HR (1)	HRP20161696T4 (es)
HU (1)	HUE031253T2 (es)
IL (2)	IL230949A (es)
IN (1)	IN2014DN01012A (es)
LT (1)	LT2744810T (es)
MA (1)	MA35350B1 (es)
MD (1)	MD4508C1 (es)
ME (1)	ME02612B (es)
MX (1)	MX336627B (es)
PE (1)	PE20141328A1 (es)
PH (1)	PH12014500349A1 (es)
PL (1)	PL2744810T5 (es)
PT (1)	PT2744810T (es)
RS (1)	RS55353B2 (es)
SG (1)	SG2014011548A (es)
SI (1)	SI2744810T2 (es)
SM (2)	SMT201600476T1 (es)
TW (1)	TWI516499B (es)
UA (1)	UA115311C2 (es)
UY (1)	UY34262A (es)
WO (1)	WO2013025788A1 (es)
ZA (1)	ZA201400582B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT201600476T1 (it)	2011-08-16	2017-03-08	Gilead Sciences Inc	Tenofovir alafenammide emifumarato
ES2661705T3 (es)	2011-10-07	2018-04-03	Gilead Sciences, Inc.	Métodos para la preparación de análogos de nucleótidos antivirales
WO2013116730A1 (en) *	2012-02-03	2013-08-08	Gilead Sciences, Inc.	Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2015040640A2 (en) *	2013-09-20	2015-03-26	Laurus Labs Private Limited	An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) *	2014-01-15	2019-06-01	美商基利科學股份有限公司	泰諾福韋之固體形式
US9463194B2 (en)	2014-02-05	2016-10-11	Gilead Sciences, Inc.	Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) *	2014-05-20	2015-11-25	四川海思科制药有限公司	替诺福韦艾拉酚胺复合物及其制备方法和用途
CN108191913A (zh) *	2014-11-12	2018-06-22	四川海思科制药有限公司	一种替诺福韦艾拉酚胺晶型a及其制备方法
CN105237571B (zh) *	2014-11-28	2018-03-09	成都苑东生物制药股份有限公司	9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) *	2014-12-11	2015-04-29	杭州和泽医药科技有限公司	一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
CN118286245A (zh)	2014-12-26	2024-07-05	埃莫里大学	N4-羟基胞苷和衍生物及与其相关的抗病毒用途
BR112017014085A2 (pt) *	2015-01-03	2018-01-09	Mylan Laboratories Ltd	processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
CN105669751B (zh) *	2015-03-05	2018-09-21	洛阳聚慧医药科技有限公司	非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) *	2015-06-01	2015-07-15	Equigerminal Sa	Antiviral composition
CZ2015384A3 (cs)	2015-06-05	2016-12-14	Zentiva, K.S.	Pevné formy Tenofovir alafenamidu
EP4092037A1 (en)	2015-06-17	2022-11-23	Gilead Sciences, Inc.	Co-crystals, salts and solid forms of tenofovir alafenamide
JP6667556B2 (ja)	2015-06-30	2020-03-18	ギリアードサイエンシーズ，インコーポレイテッド	テノホビルおよびエムトリシタビンを含む薬学的製剤
WO2017007701A1 (en) *	2015-07-07	2017-01-12	Merck Sharp & Dohme Corp.	Antiviral phosphodiamide compounds
EP3334743B1 (en)	2015-08-10	2023-11-29	Merck Sharp & Dohme LLC	Antiviral beta-amino acid ester phosphodiamide compounds
WO2017037608A1 (en) *	2015-08-28	2017-03-09	Laurus Labs Private Limited	Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
MX2018005729A (es)	2015-11-09	2018-08-09	Gilead Sciences Inc	Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
CN106699812A (zh) *	2015-11-12	2017-05-24	江苏豪森药业集团有限公司	替诺福韦前药的制备和纯化方法
WO2017100108A1 (en)	2015-12-10	2017-06-15	Merck Sharp & Dohme Corp.	Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en)	2015-12-15	2020-08-19	Merck Sharp & Dohme Corp.	Antiviral oxime phosphoramide compounds
ES2806604T3 (es)	2016-02-02	2021-02-18	Sandoz Ag	Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) *	2016-03-25	2017-10-03	江苏奥赛康药业股份有限公司	替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) *	2016-05-21	2017-11-30	Shilpa Medicare Limited	Crystalline forms of tenofovir alafenamide hemi fumarate
WO2017211325A1 (zh) *	2016-06-05	2017-12-14	上海诚妙医药科技有限公司	富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
PT3597646T (pt)	2016-08-19	2023-09-11	Gilead Sciences Inc	Compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infeção pelo vírus hiv
US10449208B2 (en)	2016-08-25	2019-10-22	Merck Sharp & Dohme Corp.	Antiviral prodrugs of tenofovir
CN107793451A (zh) *	2016-08-30	2018-03-13	江苏奥赛康药业股份有限公司	替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) *	2016-08-31	2018-03-08	Viiv Healthcare Company	Combinations and uses and treatments thereof
WO2018051250A1 (en)	2016-09-14	2018-03-22	Viiv Healthcare Company	Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en)	2016-10-26	2020-05-13	Merck Sharp & Dohme Corp.	Antiviral aryl-amide phosphodiamide compounds
CN113072583A (zh) *	2016-11-28	2021-07-06	正大天晴药业集团股份有限公司	一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) *	2016-12-01	2018-06-08	北京美倍他药物研究有限公司	磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) *	2016-12-02	2018-05-25	上海博志研新药物技术有限公司	替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
TW201829412A (zh)	2016-12-22	2018-08-16	美商默沙東藥廠	抗病毒之替諾福韋（tenofovir）之脂系酯前藥
AU2017378893A1 (en)	2016-12-22	2019-05-16	Idenix Pharmaceuticals Llc	Antiviral benzyl-amine phosphodiamide compounds
AU2017378959B2 (en)	2016-12-23	2021-09-09	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Nucleoside phosphate compound and preparation method and use thereof
WO2018115046A1 (en)	2016-12-23	2018-06-28	Sandoz Ag	Crystalline solid forms of tenofovir alafenamide
TWI714820B (zh) *	2017-01-31	2021-01-01	美商基利科學股份有限公司	替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en)	2017-02-24	2018-08-30	Hexal Ag	Stable composition of tenofovir alafenamide
RU2659388C1 (ru)	2017-02-28	2018-07-02	Васильевич Иващенко Александр	Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) *	2017-04-26	2018-11-13	上海医药工业研究院	一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) *	2017-05-31	2017-12-08	北京阜康仁生物制药科技有限公司	替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru)	2017-07-03	2018-10-22	Александрович Иващенко Андрей	Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) *	2017-09-30	2017-12-29	深圳科兴生物工程有限公司	一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) *	2017-10-23	2018-04-03	上海博悦生物科技有限公司	一种替诺福韦艾拉酚胺的药物组合物及其制备方法
US20190151307A1 (en)	2017-10-24	2019-05-23	Gilead Sciences, Inc.	Methods of treating patients co-infected with a virus and tuberculosis
AU2018378832B9 (en)	2017-12-07	2021-05-27	Emory University	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20200407382A1 (en)	2017-12-30	2020-12-31	Cipla Limited	Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
US10836746B2 (en)	2018-02-15	2020-11-17	Gilead Sciences, Inc.	Therapeutic compounds
WO2019161280A1 (en)	2018-02-16	2019-08-22	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
CN108440596B (zh) *	2018-03-22	2020-07-03	科兴生物制药股份有限公司	一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
US11186599B2 (en)	2018-06-12	2021-11-30	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
TWI842721B (zh)	2018-07-16	2024-05-21	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
US11826375B2 (en)	2018-07-19	2023-11-28	Merck Sharp & Dohme Llc	Phosphinic amide prodrugs of tenofovir
US20210393631A1 (en)	2018-09-19	2021-12-23	Gilead Sciences, Inc.	Integrase inhibitors for the prevention of hiv
EP3938047B1 (en)	2019-03-22	2022-06-22	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
KR102054104B1 (ko) *	2019-04-30	2019-12-09	유니셀랩 주식회사	신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
US20220257619A1 (en)	2019-07-18	2022-08-18	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) *	2019-08-21	2019-11-15	天地恒一制药股份有限公司	一种丙酚替诺福韦半富马酸单晶的制备方法
AU2020391466B2 (en)	2019-11-26	2024-05-23	Gilead Sciences, Inc.	Capsid inhibitors for the prevention of HIV
WO2021165995A1 (en)	2020-02-20	2021-08-26	Cipla Limited	Novel salts and/or co-crystals of tenofovir alafenamide
AU2021237718B2 (en)	2020-03-20	2023-09-21	Gilead Sciences, Inc.	Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20210125298A (ko)	2020-04-08	2021-10-18	주식회사 파마코스텍	테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
TWI858267B (zh)	2020-06-25	2024-10-11	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
CN116437958A (zh)	2020-11-11	2023-07-14	吉利德科学公司	鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
US11667656B2 (en)	2021-01-27	2023-06-06	Apotex Inc.	Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko)	2021-04-13	2022-10-20	경동제약 주식회사	신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
CA3235937A1 (en)	2021-12-03	2023-06-08	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
EP4440701A1 (en)	2021-12-03	2024-10-09	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
CN118355020A (zh)	2021-12-03	2024-07-16	吉利德科学公司	Hiv病毒感染的治疗性化合物
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en)	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AU2023330037A1 (en)	2022-08-26	2025-03-06	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en)	2022-10-04	2024-07-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (en)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024249573A1 (en)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Solid forms of compounds useful in the treatment of hiv
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
WO2025029247A1 (en)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5302585A (en) *	1990-04-20	1994-04-12	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
EP0481214B1 (en)	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Prodrugs of phosphonates
US5798340A (en)	1993-09-17	1998-08-25	Gilead Sciences, Inc.	Nucleotide analogs
US5468768A (en)	1994-01-06	1995-11-21	Bristol-Myers Squibb Company	Antimigraine derivatives of indolylcycloalkanylamines
JP4033494B2 (ja)	1996-07-26	2008-01-16	ギリヤドサイエンシーズ，インコーポレイテッド	ヌクレオチドアナログ
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE122008000033I1 (de)	1996-07-26	2008-10-02	Gilead Sciences Inc	Nukleotidanaloga
ES2249511T3 (es)	1997-07-25	2006-04-01	Gilead Sciences, Inc.	Composiciones de analogos de nucleotido y procedimiento de sintesis.
OA12393A (en) *	2000-07-21	2006-04-18	Gilead Sciences Inc	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
MY131488A (en)	2002-04-08	2007-08-30	Bristol Myers Squibb Co	Low dose liquid entecavir formulations and use
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) *	2003-03-24	2004-10-14	Canon Inc	太陽電池モジュールの製造方法
ECSP045074A (es)	2004-04-22	2004-05-28		Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
EP2332538A1 (en)	2004-05-21	2011-06-15	Japan Tobacco, Inc.	Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
WO2007013086A1 (en)	2005-07-26	2007-02-01	Hetero Drugs Limited	Novel polymorphs of tenofovir disoproxil fumarate
WO2008010921A2 (en)	2006-07-07	2008-01-24	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
EP2046792B1 (en) *	2006-07-12	2015-02-25	Mylan Laboratories Limited	Process for the preparation of tenofovir
KR101577698B1 (ko)	2007-02-23	2015-12-15	길리애드 사이언시즈, 인코포레이티드	치료제의 약동학적 특성의 조절제
AU2008253803A1 (en) *	2007-05-22	2008-11-27	Ultimorphix Technolgies B.V.	Tenofovir disoproxil hemi-fumaric acid Co-crystal
AU2009242451C1 (en)	2008-05-02	2017-05-18	Gilead Sciences, Inc.	The use of solid carrier particles to improve the processability of a pharmaceutical agent
JP5611242B2 (ja)	2009-02-06	2014-10-22	ギリアードサイエンシーズ，インコーポレイテッド	併用治療のための錠剤
US7973013B2 (en)	2009-09-21	2011-07-05	Gilead Sciences, Inc.	2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ610729A (en)	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
SMT201600476T1 (it)	2011-08-16	2017-03-08	Gilead Sciences Inc	Tenofovir alafenammide emifumarato
ES2661705T3 (es)	2011-10-07	2018-04-03	Gilead Sciences, Inc.	Métodos para la preparación de análogos de nucleótidos antivirales
WO2013116730A1 (en) *	2012-02-03	2013-08-08	Gilead Sciences, Inc.	Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

2012
- 2012-08-15 SM SM20160476T patent/SMT201600476T1/it unknown
- 2012-08-15 AR ARP120102988A patent/AR087546A1/es not_active Application Discontinuation
- 2012-08-15 MD MDA20140011A patent/MD4508C1/ro active IP Right Grant
- 2012-08-15 PL PL12753867.6T patent/PL2744810T5/pl unknown
- 2012-08-15 HR HRP20161696TT patent/HRP20161696T4/hr unknown
- 2012-08-15 DK DK12753867.6T patent/DK2744810T4/da active
- 2012-08-15 CA CA2845553A patent/CA2845553C/en active Active
- 2012-08-15 SI SI201230807T patent/SI2744810T2/sl unknown
- 2012-08-15 CN CN201910647566.6A patent/CN110343135A/zh active Pending
- 2012-08-15 AU AU2012296622A patent/AU2012296622C1/en active Active
- 2012-08-15 JP JP2014526164A patent/JP5651275B2/ja active Active
- 2012-08-15 PT PT127538676T patent/PT2744810T/pt unknown
- 2012-08-15 IN IN1012DEN2014 patent/IN2014DN01012A/en unknown
- 2012-08-15 CN CN201280039891.0A patent/CN103732594A/zh active Pending
- 2012-08-15 MX MX2014001549A patent/MX336627B/es unknown
- 2012-08-15 AP AP2014007437A patent/AP3639A/xx active
- 2012-08-15 HU HUE12753867A patent/HUE031253T2/en unknown
- 2012-08-15 EP EP16153076.1A patent/EP3070088A1/en not_active Withdrawn
- 2012-08-15 ES ES12753867T patent/ES2608871T5/es active Active
- 2012-08-15 BR BR112014003420-6A patent/BR112014003420B1/pt active IP Right Grant
- 2012-08-15 EP EP12753867.6A patent/EP2744810B2/en active Active
- 2012-08-15 WO PCT/US2012/050920 patent/WO2013025788A1/en active Application Filing
- 2012-08-15 TW TW101129542A patent/TWI516499B/zh active
- 2012-08-15 US US13/586,358 patent/US8754065B2/en active Active
- 2012-08-15 LT LTEP12753867.6T patent/LT2744810T/lt unknown
- 2012-08-15 KR KR1020147003886A patent/KR101612642B1/ko active Active
- 2012-08-15 PH PH1/2014/500349A patent/PH12014500349A1/en unknown
- 2012-08-15 UA UAA201401084A patent/UA115311C2/uk unknown
- 2012-08-15 UY UY0001034262A patent/UY34262A/es active IP Right Grant
- 2012-08-15 FI FIEP12753867.6T patent/FI2744810T4/fi active
- 2012-08-15 PE PE2014000206A patent/PE20141328A1/es active IP Right Grant
- 2012-08-15 ME MEP-2016-273A patent/ME02612B/me unknown
- 2012-08-15 SG SG2014011548A patent/SG2014011548A/en unknown
- 2012-08-15 EP EP20206486.1A patent/EP3831832A1/en active Pending
- 2012-08-15 RS RS20161018A patent/RS55353B2/sr unknown
- 2012-08-15 EA EA201490208A patent/EA027768B1/ru active Protection Beyond IP Right Term
2014
- 2014-01-24 ZA ZA2014/00582A patent/ZA201400582B/en unknown
- 2014-02-12 CR CR20140072A patent/CR20140072A/es unknown
- 2014-02-12 CO CO14029801A patent/CO6880063A2/es unknown
- 2014-02-12 MA MA36754A patent/MA35350B1/fr unknown
- 2014-02-13 IL IL230949A patent/IL230949A/en active IP Right Grant
- 2014-02-13 CL CL2014000370A patent/CL2014000370A1/es unknown
- 2014-02-13 EC ECSP14013206 patent/ECSP14013206A/es unknown
- 2014-03-05 US US14/197,873 patent/US9296769B2/en active Active
- 2014-11-14 JP JP2014231819A patent/JP5956537B2/ja active Active
- 2014-12-11 HK HK14112467.3A patent/HK1199026A1/xx active IP Right Maintenance
2015
- 2015-08-18 IL IL240649A patent/IL240649A0/en unknown
2016
- 2016-06-16 JP JP2016120153A patent/JP6280162B2/ja active Active
- 2016-12-22 CY CY20161101331T patent/CY1118385T1/el unknown
- 2016-12-28 SM SM201600476T patent/SMT201600476B/it unknown
2018
- 2018-01-18 JP JP2018006107A patent/JP2018065870A/ja not_active Withdrawn
2019
- 2019-11-21 JP JP2019210196A patent/JP2020040972A/ja active Pending

Also Published As

Publication number	Publication date
AU2012296622B2 (en)	2014-09-11
TWI516499B (zh)	2016-01-11
IL230949A (en)	2015-09-24
EA027768B1 (ru)	2017-08-31
MA35350B1 (fr)	2014-08-01
JP2016169228A (ja)	2016-09-23
JP2014528924A (ja)	2014-10-30
CA2845553C (en)	2019-05-28
MD4508C1 (ro)	2018-03-31
CO6880063A2 (es)	2014-02-28
EP2744810A1 (en)	2014-06-25
IL240649A0 (en)	2015-09-24
EP3831832A1 (en)	2021-06-09
RS55353B2 (sr)	2023-11-30
SMT201600476B (it)	2017-03-08
SMT201600476T1 (it)	2017-03-08
EP2744810B2 (en)	2023-09-13
US20140187773A1 (en)	2014-07-03
WO2013025788A1 (en)	2013-02-21
AU2012296622C1 (en)	2017-02-16
CN110343135A (zh)	2019-10-18
CL2014000370A1 (es)	2014-09-05
BR112014003420A2 (pt)	2017-03-01
EA201490208A1 (ru)	2014-06-30
UY34262A (es)	2013-04-05
IN2014DN01012A (es)	2015-05-15
RS55353B1 (sr)	2017-03-31
HRP20161696T4 (hr)	2023-10-13
HUE031253T2 (en)	2017-07-28
SI2744810T2 (sl)	2023-11-30
TW201321396A (zh)	2013-06-01
JP2015038149A (ja)	2015-02-26
CR20140072A (es)	2014-06-19
ES2608871T3 (es)	2017-04-17
KR101612642B1 (ko)	2016-04-14
PL2744810T5 (pl)	2024-02-05
JP2018065870A (ja)	2018-04-26
HRP20161696T1 (hr)	2017-02-24
ECSP14013206A (es)	2014-03-31
AU2012296622A1 (en)	2013-05-09
JP2020040972A (ja)	2020-03-19
JP5956537B2 (ja)	2016-07-27
AP3639A (en)	2016-03-13
ME02612B (me)	2017-06-20
CN103732594A (zh)	2014-04-16
ZA201400582B (en)	2017-11-29
SG2014011548A (en)	2014-09-26
PL2744810T3 (pl)	2017-04-28
PE20141328A1 (es)	2014-10-04
MD4508B1 (ro)	2017-08-31
JP5651275B2 (ja)	2015-01-07
EP3070088A1 (en)	2016-09-21
PH12014500349A1 (en)	2016-04-06
CY1118385T1 (el)	2017-06-28
DK2744810T3 (en)	2016-12-05
BR112014003420B1 (pt)	2021-07-20
JP6280162B2 (ja)	2018-02-14
LT2744810T (lt)	2016-11-25
EP2744810B1 (en)	2016-10-05
FI2744810T4 (fi)	2023-11-22
MD20140011A2 (en)	2014-05-31
US8754065B2 (en)	2014-06-17
NZ620421A (en)	2015-05-29
US9296769B2 (en)	2016-03-29
AR087546A1 (es)	2014-04-03
DK2744810T4 (da)	2023-11-20
MX336627B (es)	2016-01-26
IL230949A0 (en)	2014-03-31
PT2744810T (pt)	2016-11-04
MX2014001549A (es)	2014-02-27
SI2744810T1 (sl)	2017-01-31
UA115311C2 (uk)	2017-10-25
ES2608871T5 (es)	2024-04-04
US20130065856A1 (en)	2013-03-14
AP2014007437A0 (en)	2014-02-28
KR20140054068A (ko)	2014-05-08
CA2845553A1 (en)	2013-02-21

Publication	Publication Date	Title
HK1199026A1 (en)	2015-06-19	Tenofovir alafenamide hemifumarate (tenofoviralafenamide)
EP2717099A4 (en)	2014-12-17	TONER
EP2717100A4 (en)	2015-03-04	TONER
EP2710430A4 (en)	2014-10-22	INK POWDER
EP2722937A4 (en)	2014-10-22	CONNECTOR
EP2725661A4 (en)	2015-03-18	CONNECTOR
EP2710432A4 (en)	2014-11-12	TONER
EP2691815A4 (en)	2014-09-03	TONER
EP2710431A4 (en)	2014-11-12	TONER
HK1200314A1 (en)	2015-08-07	R()-n-methyl-propargyl-aminoindan r()-n---
EP2665133A4 (en)	2014-07-16	CONNECTOR
HK1200315A1 (en)	2015-08-07	R()-n-formyl-propargyl-aminoindan r()-n---
EP2686599A4 (en)	2014-09-03	QUICK COUPLING
EP2753982A4 (en)	2015-06-03	TONER
EP2750252A4 (en)	2015-06-03	CONNECTOR
EP2720321A4 (en)	2014-10-22	INTERCONNECTS
EP2743774A4 (en)	2015-03-18	IMAGE TRAINING UNIT
ZA201403228B (en)	2017-08-30	Heterocyclypyri(mi)dinylpyrazole
EP2755284A4 (en)	2015-04-15	INTERCONNECTS
HK1198841A1 (en)	2015-06-12	Plate-film forming member
GB201121309D0 (en)	2012-01-25	Antiviral
GB201102529D0 (en)	2011-03-30	Fine B-Day
GB201109708D0 (en)	2011-07-27	Compliance system
GB201116059D0 (en)	2011-11-02	Project P
GB201111218D0 (en)	2011-08-17	Sequence

Legal Events

Date	Code	Title	Description
2024-03-01	AM43	Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)